코스닥 이야기
Quickly browse recent reports in the selected category.
-
![[KOSDAQ Story] Contrary Thinking in the 1,500 KRW High Exchange Rate Era: Simmtech (222800) vs. MK Electron (033160) Export-Heavy IT Component Benefit Comparison](https://daily-stock.kr/stdaily/uploads/202606/gen_6a2fb1885bfb73.04110674.png)
[KOSDAQ Story] Contrary Thinking in the 1,500 KRW High Exchange Rate Era: Simmtech (222800) vs. MK Electron (033160) Export-Heavy IT Component Benefit Comparison
Daily Stock delivers an in depth comparison of Simmtech and MK Electron, two KOSDAQ listed IT component leaders with over 70% of revenues from exports...
-
![[KOSDAQ Story] Leeno Industrial (058470): Overhang Cleared After 730 Billion KRW Block Deal and Surging AI Testing Demand — Checking the Rebound Scenario](https://daily-stock.kr/stdaily/uploads/202606/gen_6a2e5fdbaa33d9.88742367.png)
[KOSDAQ Story] Leeno Industrial (058470): Overhang Cleared After 730 Billion KRW Block Deal and Surging AI Testing Demand — Checking the Rebound Scenario
DailyStock analyzes the successful 731.5 billion KRW block deal of Leeno Industrial 058470 , clearing overhang risks. Coupled with high margin AI test...
-
KOSDAQ Hits 996 Mark Triggers 'Buying Sidecar', Game Stocks Surge as Crimson Desert Surpasses 6 Million Units Sold with H2 New Releases Pipeline
Despite global macro risks and geopolitical tensions, the KOSDAQ market staged a dramatic rebound, nearing the 1,000 threshold. Game stocks are leadin...
-
Kosdaq at 951 level; Chunbo (278280) Hits 52-Week Low... KRW 100 Billion CB Put Option Risk Drags Down Stock Despite Defense from Advanced Semiconductor Materials
Chunbo 278280 hit a 52 week low of KRW 37,250 during trading before closing at KRW 39,650 on June 10, 2026. Despite its semiconductor materials busine...
-
Analyzing KOSDAQ 150 PSR Valuations Amid a 'Sidecar' Rebound: Financials and Discrepancy Ratios for Fadu, Satrec Initiative, and Hyundai Movex
Amid a sharp market rebound triggered by a KOSDAQ sidecar, this analysis evaluates the PSR valuations and financial health of three key KOSDAQ 150 can...
-
![[KOSDAQ Story] HLB (028300) Clinical Trials & FDA Approval Timeline Amid Black Monday Crash: Critical Milestones for Liver Cancer in July and Cholangiocarcinoma in September](https://daily-stock.kr/stdaily/uploads/202606/gen_6a2676d12d4578.84092915.png)
[KOSDAQ Story] HLB (028300) Clinical Trials & FDA Approval Timeline Amid Black Monday Crash: Critical Milestones for Liver Cancer in July and Cholangiocarcinoma in September
HLB faces major commercialization milestones with upcoming FDA decisions: the PDUFA target date for its liver cancer therapy on July 23, 2026, and a d...